Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for lipoprotein disorders.

Uli C Broedl1, Daniel J Rader

  • 1University of Munich, Department of InternalMedicine II, Marchioninistr. 15, 81377 Munich, Germany. uli.broedl@med.uni-muenchen.de

Expert Opinion on Biological Therapy
|July 30, 2005
PubMed
Summary

Somatic gene therapy offers a promising new avenue for treating lipid disorders like hypercholesterolaemia when traditional methods fail. Clinical trials are underway, suggesting a future where gene therapy is a viable option for these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

The New England journal of medicine·2017
Same author

Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms.

Nature genetics·2017
Same author

Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress.

Cell reports·2017
Same author

Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.

Circulation research·2017
Same author

Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity.

The Journal of clinical investigation·2017
Same author

Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis.

The Journal of biological chemistry·2017

Area of Science:

  • Lipid Metabolism and Genetics
  • Molecular Medicine
  • Translational Therapeutics

Background:

  • Current treatments for dyslipidaemia, including hypercholesterolaemia and hypertriglyceridaemia, are insufficient for many patients.
  • Inherited disorders of intracellular lipid metabolism also present significant therapeutic challenges.
  • Refractory lipid disorders necessitate novel treatment strategies beyond conventional approaches.

Purpose of the Study:

  • To explore somatic gene therapy as a potential treatment for various lipid disorders.
  • To review the current status of preclinical and clinical research in gene therapy for dyslipidaemia.
  • To assess the future prospects of gene therapy in managing complex lipid metabolism disorders.

Main Methods:

  • Review of existing preclinical proof-of-principle studies for somatic gene therapy in lipid disorders.

Related Experiment Videos

  • Analysis of the conducted clinical trial for homozygous familial hypercholesterolaemia.
  • Assessment of the pipeline for future gene therapy clinical trials in dyslipidaemia.

    • Main Results:

    • Preclinical evidence supports the potential of somatic gene therapy for several lipid disorders.
    • A clinical trial has been successfully conducted for homozygous familial hypercholesterolaemia.
    • Gene therapy approaches are advancing towards clinical application for dyslipidaemia.

    Conclusions:

    • Somatic gene therapy represents a promising therapeutic frontier for refractory lipid disorders.
    • The progression from preclinical studies to clinical trials indicates the feasibility of gene therapy for dyslipidaemia.
    • Further clinical trials are anticipated, highlighting the growing role of gene therapy in managing lipid metabolism diseases.